MedTrace Logo

MYLUNG Consortium Study Protocol 2

NCT05644808 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1002

Last updated 2026-05-18

No results posted yet for this study

Summary

This pragmatic study looks to quantify the testing timeline, operational barriers, and outcomes of biomarker-guided therapy in a large, community-based, and largely unselected patient population with early stage and advanced stage, treatment-naive non-small cell lung cancer, whether squamous or non-squamous.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Sponsors & Collaborators

  • US Oncology Research

    lead INDUSTRY

Principal Investigators

  • Makenzi Evangelist, MD · New York Oncology Hematology

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-29
Primary Completion
2027-09-30
Completion
2027-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05644808 on ClinicalTrials.gov